Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and application prospects of radiotherapy in neoadjuvant therapy for stage III non‐small cell lung cancer. Focusing on three core techniques: spatially fractionated radiotherapy, stereotactic body radiotherapy, and low‐d...
Qin-Rong Mao, Yuan-Chun Yu, Yan Fang et al.· Cancer Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.